Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
3 hedge funds and large institutions have $30K invested in Loncar China BioPharma ETF in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
25% less funds holding
Funds holding: 4 → 3 (-1)
98% less capital invested
Capital invested by funds: $1.74M → $30K (-$1.71M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$1.64M |
| 2 |
Morgan Stanley
New York
|
-$44.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $17K | -$6.16K | -278 | -25% |
|
|
BBPWM
2
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $9K | – | – | – |
|
|
3
Morgan Stanley
New York
| $4K | -$44.3K | -2,000 | -91% |
|
|
4
Jane Street
New York
| – | -$1.64M | -61,266 | Closed |
|
CHNA Hedge Fund Activity: Q1 2022 in Review
3 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q1 2022, worth a combined $30K — down 98% from $1.74M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CHNA and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest seller was Jane Street, exiting entirely with an estimated $1.64M sold.
- 3 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q1 2022, down from 4 in Q4 2021.
- Funds reported $30K of Loncar China BioPharma ETF stock for Q1 2022, down 98% quarter-over-quarter.
- 0 funds opened new Loncar China BioPharma ETF positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest Loncar China BioPharma ETF seller in Q1 2022 was Jane Street, an estimated $1.64M sold.
Based on aggregated 13F filings for Q1 2022.